Decision Support Tool Increases SGLT2i, GLP-1RA Use in T2DM Care Tags hBA1c GLP-1 agonists SGLT-2 Inhibitor Read more about Decision Support Tool Increases SGLT2i, GLP-1RA Use in T2DM Care
SGLT2 Inhibitors Linked to Higher DKA Risk at Elevated HbA1c Tags Diabetic ketoacidosis hBA1c SGLT-2 Inhibitor Read more about SGLT2 Inhibitors Linked to Higher DKA Risk at Elevated HbA1c
Empagliflozin or Dapagliflozin for Cardiorenal Outcomes in T2DM? Tags Myocardial infarction Stroke SGLT-2 Inhibitor Read more about Empagliflozin or Dapagliflozin for Cardiorenal Outcomes in T2DM?
Do SGLT2i and DPP-4i Differ in Hematologic Malignancy Risk? Tags DPP-4 inhibitors SGLT-2 Inhibitor Read more about Do SGLT2i and DPP-4i Differ in Hematologic Malignancy Risk?
Empagliflozin Associated With Lower EAT Thickness in T2DM Tags Echocardiography hBA1c SGLT-2 Inhibitor Read more about Empagliflozin Associated With Lower EAT Thickness in T2DM
Downstream Medication Use Differs After GLP-1 vs SGLT2 Start in T2DM Tags GLP-1 agonists SGLT-2 Inhibitor Read more about Downstream Medication Use Differs After GLP-1 vs SGLT2 Start in T2DM
Combination Therapy Tied to Reduced Colon Cancer Risk in T2DM Tags GLP-1 agonists SGLT-2 Inhibitor Read more about Combination Therapy Tied to Reduced Colon Cancer Risk in T2DM
SGLT2 Inhibitor Use Linked to Higher Knee Replacement Risk Tags SGLT-2 Inhibitor Read more about SGLT2 Inhibitor Use Linked to Higher Knee Replacement Risk
No Higher Amputation Risk Seen With SGLT2 Inhibitors in DFU Tags Peripheral vascular disease Diabetic foot. SGLT-2 Inhibitor Read more about No Higher Amputation Risk Seen With SGLT2 Inhibitors in DFU
DKA Risk Similar Across Kidney Function Levels in Type 1 Diabetes Tags Diabetic ketoacidosis SGLT-2 Inhibitor Read more about DKA Risk Similar Across Kidney Function Levels in Type 1 Diabetes